Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Earnings Results, Misses Estimates By $0.02 EPS

Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02), Zacks reports.

Brainstorm Cell Therapeutics Stock Down 11.9 %

BCLI stock opened at $1.19 on Monday. Brainstorm Cell Therapeutics has a 52 week low of $1.05 and a 52 week high of $11.25. The firm has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $2.00. The stock has a market capitalization of $6.79 million, a P/E ratio of -0.25 and a beta of 0.74.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research report on Wednesday, March 26th. They set a “hold” rating on the stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.